Profit Margin (Quarterly) Chart

View Profit Margin (Quarterly) for GILD.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Profit Margin (Quarterly) Chart
Start Trial

Historical Profit Margin (Quarterly) Data

View and export this data back to 1998. Start Trial.
Date Value
June 30, 2026 -134.2%
March 31, 2026 28.94%
December 31, 2025 27.44%
September 30, 2025 39.21%
June 30, 2025 27.75%
March 31, 2025 19.79%
December 31, 2024 23.58%
September 30, 2024 16.64%
June 30, 2024 23.23%
March 31, 2024 -62.37%
December 31, 2023 19.94%
September 30, 2023 30.87%
June 30, 2023 15.77%
March 31, 2023 15.57%
December 31, 2022 22.35%
September 30, 2022 25.54%
June 30, 2022 18.26%
March 31, 2022 0.18%
December 31, 2021 5.19%
September 30, 2021 34.75%
June 30, 2021 24.31%
March 31, 2021 26.71%
December 31, 2020 20.78%
September 30, 2020 5.38%
June 30, 2020 -65.29%
Date Value
March 31, 2020 27.86%
December 31, 2019 45.98%
September 30, 2019 -20.96%
June 30, 2019 33.19%
March 31, 2019 37.47%
December 31, 2018 0.05%
September 30, 2018 37.46%
June 30, 2018 31.95%
March 31, 2018 29.96%
December 31, 2017 -64.14%
September 30, 2017 41.48%
June 30, 2017 43.06%
March 31, 2017 41.77%
December 31, 2016 42.37%
September 30, 2016 44.28%
June 30, 2016 44.91%
March 31, 2016 46.28%
December 31, 2015 55.95%
September 30, 2015 56.29%
June 30, 2015 55.81%
March 31, 2015 58.16%
December 31, 2014 47.60%
September 30, 2014 45.08%
June 30, 2014 55.70%
March 31, 2014 44.28%

Profit Margin Definition

Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.

Read full definition.

Profit Margin (Quarterly) Range, Past 5 Years

View Profit Margin (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Profit Margin (Quarterly) Benchmarks

View Profit Margin (Quarterly) Benchmarks
Start Trial
Vertex Pharmaceuticals, Inc. 32.89%
AbbVie, Inc. 21.21%
Regeneron Pharmaceuticals, Inc. 30.23%
Amgen, Inc. 23.59%
Biogen, Inc. 3.72%